Kurma Partners, a key European venture capital company in the field of Life Sciences, announced the final closing of its third therapeutic fund, Kurma Biofund III, for €160 million, exceeding the initial objective.
The fund, dedicated to the financing and development of European therapeutic and medical innovation, has notably benefitted from the support of leading European investors such as Servier.
“As cornerstone investor in this fund, we are delighted with the fund raising success and the unique set of Limited Partners. The Kurma team has shown impressive execution over the past 15 months with 8 transactions closed. We are proud that this strategic partnership will help companies bring breakthrough therapies to patients” commented Olivier Laureau, President of Servier.
This new fund aims to finance 12 to 15 Life Sciences companies and has already participated in the creation of 5 biotechs in Europe.